NTX-301 in MDS/AML
NTX-301 is a DNMT1 inhibitor. The drug is an oral drug with preclinical data that has shown preclinical anti-leukemic efficacy. This is the first clinical trial using NTX-301 in patients with myeloid malignancies.
Acute Myeloid Leukemia|Myelodysplastic Syndromes|Chronic Myelomonocytic Leukemia
DRUG: NTX-301
Safety/tolerability: Incidence of treatment related adverse events (AEs) and dose-limiting toxicities (DLTs), 3 years
Efficacy: Clinical Benefit Rate (CBR), Clinical Benefit Rate (CBR), as defined as the percentage of participants achieving a complete remission (CR), complete marrow remission (mCR), partial remission (PR), stable disease (SD) lasting at least 8 weeks, or hematologic improvement (HI), per International Working Group (IWG) criteria., 3 years|Efficacy: Overall response rate (ORR), Overall response rate (ORR), defined as the percentage of participants achieving a CR, mCR, or PR, per IWG criteria., 3 years|Efficacy: Progression free survival (PFS), Progression free survival (PFS), defined as time from first dose to disease progression, as defined by IWG criteria, or death due to any cause, whichever occurs earlier., 3 years|Efficacy: Overall survival (OS), Overall survival (OS), defined as time from first dose to death due to any cause., 3 years|Pharmacodynamics (PD): Global methylation (assay) in blood and/or marrow leukemia samples, 3 years|Pharmacokinetics (PK): Area under the curve (AUC), 3 years|Pharmacokinetics (PK): Maximum plasma concentration (Cmax), 3 years|Pharmacokinetics (PK): Time to reach maximum concentration (Tmax), 3 years|Pharmacokinetics (PK): Half life (t1/2), 3 years
NTX-301 is a DNMT1 inhibitor. The drug is an oral drug with preclinical data that has shown preclinical anti-leukemic efficacy. This is the first clinical trial using NTX-301 in patients with myeloid malignancies.